Evidence map›Paper›PMID 39925385›Full record

ArticleData in brief2025

Dataset of transcriptomic changes induced by naringenin treatment in MCF-7 breast cancer cells.

Van T Hoang, Mackenzie L Hawes, Jack R Elliott, Steven Elliott, Binghao Zou, Stephen M Boué, Brian G Rowan, Bridgette M Collins-Burow, Jorge A Belgodere, Muralidharan Anbalagan and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Data in brief, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Van T HoangTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Mackenzie L HawesTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Jack R ElliottTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Steven ElliottTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Binghao ZouDepartment of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Stephen M BouéU. S. Department of Agriculture, Agricultural Research Service, Southern Regional Research Center, New Orleans, LA 70179, USA.
Brian G RowanDepartment of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Bridgette M Collins-BurowTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Jorge A BelgodereTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Muralidharan AnbalaganDepartment of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Elizabeth C MartinTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Matthew E BurowTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Naringenin (Nar) is a citrus fruit-derived phytoestrogen, a group of dietary compounds produced by a wide variety of plants. Due to structural similarity to 17-β-estradiol (E2), phytoestrogens can bind to estrogen receptors (ERs) to exert context-dependent estrogenic and/or anti-estrogenic effects. As such, there are potential health benefits and risks associated with phytoestrogen exposure. To investigate the effects of Nar in breast cancer, based on its activity as a phytoestrogen, we treated MCF-7 ER-positive (ER+) breast cancer cells with Nar (10 µM) and examined transcriptomic changes in MCF-7 cells induced by Nar treatment. Pathway analysis included in our dataset shows upregulation of genes associated with estrogen signaling and epithelial-to-mesenchymal transition in breast cancer cells treated with naringenin.

Indexed as

Dietary compoundsEpithelial to mesenchymal transitionEstrogen responsePhytoestrogenPlant-derived compoundsRNA-seq

Identifiers

PMID39925385
PMCPMC11803210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.